Two starting prices on one dark-spot cream page: retain the conflict

The current Spot On offer shows a three-month plan with a $165 total and a displayed monthly amount of $54.99. Its one-month option shows $70 alongside $69.99 monthly wording. The product page also advertises a starting monthly price of $54.99. These are observations of public pages checked on September 27, 2026. Offer cards and the product page are the sources.

The totals and the displayed monthly figures should both survive a summary. Their small arithmetic differences are not permission to invent the seller's rounding or charging method. A public display is also not evidence of the charge shown to a particular person after review, or proof that a stated total is collected in monthly installments.

Elsewhere on the same offer, the section explaining what Spot On is gives a starting price of $42 monthly. It appears beside the formula's own identity and dispensing description. That matters because the page also mentions other CoreAge products; this particular discrepancy cannot be dismissed simply as one of their prices. The same-product statement remains in the inspected record.

No matching $42 Spot On plan was established by the checked main cards. The CoreAge review records the conflict as unresolved. Calling the lower amount a hidden discount, an older offer or a certain checkout price would add an explanation that these documents do not provide.

A plan described in months does not identify the weight of cream, container count or amount in a shipment. Spot On's reviewed material names its advertised actives and plan periods but does not establish those physical supply details. The offer cannot support a per-container or per-weight comparison from the information available here.

A useful written quote would connect the product name, prescribed preparation, quantity and total charge. That is a question for the seller and responsible dispensing professional, not a calculation this guide can complete from a month label. The product-label guide distinguishes a commercial supply description from the contents information that belongs with the actual item.

Obagi Clear Fx currently displays a regular retail price of $125. Its page describes an arbutin-based brightening cream. The separate prescription Nu-Derm Clear page identifies hydroquinone 4% and directs readers toward a healthcare professional; the Fx price does not fill in a missing prescription quote. Fx and prescription Clear must remain separate records.

The Clear Fx review examines that retail offering on its own terms. A shared brand family or search result does not justify moving a price, return headline or review score from one preparation to another. Matching the complete name comes before deciding whether the figures can be compared at all.

A full transaction may involve professional assessment, medication, dispensing and delivery. The publicly displayed number does not automatically settle all of those components or explain what happens after a prescription is prepared. Spot On advertises free shipping, describes a refund if prescribing is not approved, and refers readers to separate prescription-product return terms. Those statements remain narrower than a verified universal refund policy. Current offer language provides the record.

The provider comparison keeps differences in product and service categories visible. The relevant question is which terms apply to the exact proposed order, including billing frequency and future charges. No order or payment flow was completed for this publication, so it cannot confirm those individual answers.

Spot On's offer links longer plans with better results. That is a marketing assertion, not an outcome established by the plan-price table. FTC health-products guidance says evidence must be relevant to the specific product and benefit being claimed. A billing period alone does not meet that evidentiary task. FTC's guidance supports examining the connection rather than assuming it.

Separately, AAD describes melasma care as tailored to the individual after assessment. Its clinical context does not let a sales period determine a person's treatment course. The professional question is about appropriate care and review, while the commercial question is about what is being purchased. A lower displayed monthly amount cannot answer both.

The claim-records reader preserves product identity, price wording and the limits of an offer as separate fields. It does not score affordability or select a plan. A seller's clarification can answer a financial question; a clinician's assessment addresses the medical one. Neither should be inferred from the publication's ordering of providers.

The Spot Check is part of the CoreAge Rx promotional publishing network and gives CoreAge first commercial placement. That relationship is disclosed, not presented as a reason to accept its lowest price claim. Retaining the conflict gives readers a concrete question to ask while avoiding a promise that the public evidence cannot support.